Point Of Care Infectious Disease Testing Market Size | Top Companies
The global point of care infectious disease testing market size is expected to be worth around USD 18.26 Billion by 2033 from USD 11.87 Billion in 2023, growing at a Compound Annual Growth Rate (CAGR) of 4.4% during the forecast period from 2024 to 2033.
The market is driven by the rising infectious diseases, demand for precise diagnostics tools and technological advancements such as molecular diagnostics & agglutination test. The rising contagious disease and increasing aging population along with the supportive government policies promoting the adoption of point of care (POC) testing are the factors likely to fuel the market growth during the forecast period.
The rising demand for diagnostic tools is increasing due to the increasing number of infectious diseases such as HIV, hepatitis, and tuberculosis. These point-of-care tests are becoming more common as many illnesses need to be found early to be treated as soon as possible. There is an increasing shift towards rising communicable diseases and rise in home healthcare preferred by many patients, especially the elderly and individuals with chronic conditions such as heart disease, diabetes and cancer. This shift contributes to POC diagnostics tools by allowing tests to be done outside typical medical places, even at home. This brings benefits like convenience, lower expenses, and more control for patients. Easy-to-use POC tests give accurate results, letting patients keep tabs on their health and require fewer doctor hospital visits.
| Report Attribute | Details |
| Market Size in 2024 | USD 12.39 Billion |
| Market Size by 2033 | USD 18.26 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.4% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, disease, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Abbott; Thermo Fisher Scientific Inc; F. Hoffmann-La Roche Ltd; Siemens Healthineers; Becton, Dickinson & Company; Chembio Diagnostics Inc.; Trinity Biotech; Cardinal Health; Quest Diagnostics Incorporated; Bio-Rad Laboratories Inc.; bioMérieux SA; Sight Diagnostics Ltd.; Gene POC; Trivitron Healthcare; OJ-Bio Ltd.; Ortho-Clinical Diagnostics.; |
Disease Insights
COVID-19 segment dominated the market and accounted for a share of 67.22% in 2023. This high percentage can be attributed to the rising number of infectious cases and need for fast and accessible diagnostics testing solutions. Point-of-care tests were crucial as they delivered results quickly, allowing for rapid identification and management of cases. These tests could be done outside traditional labs, like in clinics or even at home, making them highly convenient.
The pneumonia or streptococcus associated infections segment is anticipated to witness the fastest CAGR during the forecast period, owing to the rising cases of communicable disease and developments of new drugs in treatment of disease. Pneumococcal disease is caused by bacteria called Streptococcus pneumonia. Streptococcus bacteria are very common and can be spread easily through an infected person owing to rapid diagnosis importance to the disease. POC test provides faster results, allowing for faster treatments.
Technology Insights
Molecular diagnostics accounted for the largest market revenue share of 43.18% in 2023, owing to rising number of patients due to infectious disease and advancements in molecular testing. Molecular tests are highly accurate and capable of detecting genetic materials. Molecular diagnostics devices deliver faster and accurate results, which is essential for patient care and helpful for doctors for quicker treatment decisions.
Lateral flow immunoassay is expected to register the fastest CAGR of 5.7% during the forecast period. The growth can be attributed to increasing prevalence of infectious diseases such as respiratory disease and technological advancements in point of care diagnostics device. A lateral flow immunoassay is a diagnostic device that confirms the presence of substance from a sample. Lateral flow tests are portable and lightweight and are great for point of care settings such as homes, offices and remote regions with small healthcare facilities. The rise in consumer demand for lateral flow immunoassay devices is likely to drive the growth due to its several benefits.
End Use Insights
The clinics segment dominated the market in 2023. The growth can be attributed to increasing establishments of point of care diagnostics laboratory centers and rising number of communicable diseases. Clinics play a crucial role serving as an important point of care center for treating and testing patients for various diseases such as TB, etc.
The home segment is projected to grow at the fastest CAGR of 5.5% over the forecast period, owing to increasing adoption of point of care testing among geriatric population and increasing emphasis on personalized and preventive home care facilities. Home care provides patients with convenience and accessibility. Easy-to-use tools for diagnosing infectious diseases at home allow patients to test themselves without requiring healthcare professionals. Moreover, convenience encourages people to manage their health better by getting tested quickly, which helps find and treat infectious diseases early.
Regional Insights
North America point of care infectious disease testing market dominated the market with the revenue share of 51.33% in 2023 owing to the rising number of infectious and advancements in technology. The presence of advanced healthcare infrastructure, high adoption of point of care testing and home to some of largest companies operating in point of care infectious disease testing market are some of the factors propelling the market growth. Moreover, the rising healthcare expenditure and increasing geriatric population in countries such as U.S. Canada & Mexico is boosting the region growth.
U.S. Point Of Care Infectious Disease Testing Market Trends
The U.S. point of care infectious disease diagnostics dominated the North America market with a share of 82.6% in 2023 due to rising number of infectious in the nation. According to centers for disease control and prevention, there were more than 9,500 cases of TB registered in 2023, a 16% increase from 2022. Furthermore, the country has a robust infrastructure for research and development and a better advanced healthcare system.
Europe Point Of Care Infectious Disease Testing Market Trends
Europe point of care infectious disease testing market was identified as a lucrative region in 2023. The growth can be attributed to the increasing prevalence of infectious disease. Rising healthcare expenditure and growing awareness among people for point of care testing is driving the region’s growth. The private sector is playing a crucial role in development of new diagnostics devices which are easy to use and convenient.
The UK point of care infectious disease testing market is expected to grow rapidly in the coming years due to increasing number of communicable disease and public health initiatives. The UK government focuses strong emphasis on public health and preventing health issues, with support from organizations such as National Health Service. Furthermore, the health initiatives and research & development by the UK government is likely to contribute to the growth in the country.
The point of care infectious disease testing market in Germany held a substantial market share in 2023 owing to increasing geriatric population and rising prevalence of infectious disease. The country possesses robust healthcare infrastructure and ranks 3rd in healthcare innovation. Moreover, the government policy and initiatives for healthcare system such as mandatory health insurance for all residents is likely to propel the region’s growth.
Asia Pacific Point Of Care Infectious Disease Testing Market Trends
Asia Pacific market point of care infectious disease diagnostics is anticipated to witness the fastest CAGR of 5.0% during the forecast period. This growth is due to the significantly increasing population in the region and rising infectious diseases. Infectious diseases are more common compared to other places and infectious diseases spread easily due to large and rising geriatric population in countries like China, Japan and India. The rising demand for fast and easy ways to diagnose the disease is fueling the growth.
The China point of care infectious disease testing market held a substantial market share in 2023 driven by large population and rising cases of infectious diseases such as TB, and hepatitis. The adoption of advanced diagnostic medical devices such as molecular diagnostics and lateral flow immunoassay are fueling the country’s growth.
The point of care infectious disease testing market in India is expected to witness significant growth during the forecast period, owing to the increasing population, rise in prevalence of communicable disease in children under age of 3 and population over the age of 65.
The following are the leading companies in the point of care infectious disease testing market. These companies collectively hold the largest market share and dictate industry trends.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Point Of Care Infectious Disease Testing market.
By Technology
By Disease
By End Use
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Point of Care Infectious Disease Testing Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Point of Care Infectious Disease Testing Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Point of Care Infectious Disease Testing Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Point of Care Infectious Disease Testing Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
4.3. Lateral Flow Immunoassay
4.3.1. Lateral Flow Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.4. Agglutination Test
4.4.1. Agglutination Test Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.5. Flow-through test/Immunoconcentration Assay
4.5.1. Flow-through test/Immunoconcentration Assay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.6. Molecular Diagnostics
4.6.1. Molecular Diagnostics Test Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.7. Others
4.7.1. Others Test Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. Point of Care Infectious Disease Testing Market: Disease Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Point of Care Infectious Disease Testing Market: Disease Movement Analysis, 2023 & 2030 (USD Billion)
5.3. HIV POC
5.3.1. HIV POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.4. Clostridium Difficile POC
5.4.1. Clostridium Difficile POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.5. HBV POC
5.5.1. HBV POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.6. Pneumonia or Streptococcus Associated Infections
5.6.1. Pneumonia or Streptococcus Associated Infections Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.7. Respiratory Syncytial Virus (RSV) POC
5.7.1. Respiratory Syncytial Virus (RSV) POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.8. HPV POC
5.8.1. HPV POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.9. Influenza/Flu POC
5.9.1. Influenza/Flu POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.10. HCV POC
5.10.1. HCV POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.11. MRSA POC
5.11.1. MRSA POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.12. TB and Drug-resistant TB POC
5.12.1. TB and Drug-resistant TB POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.13. HSV POC
5.13.1. HSV POC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.14. COVID-19
5.14.1. COVID-19 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.15. Other Infectious Diseases
5.15.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. Point of Care Infectious Disease Testing Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Point of Care Infectious Disease Testing Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
6.3. Clinics
6.3.1. Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4. Hospitals
6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.5. Home
6.5.1. Home Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.6. Assisted Living Healthcare Facilities
6.6.1. Assisted Living Healthcare Facilities Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.7. Laboratory
6.7.1. Laboratory Facilities Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. Point of Care Infectious Disease Testing Market: Regional Estimates & Trend Analysis
7.1. Point of Care Infectious Disease Testing Market Share, By Region, 2023 & 2030 (USD Billion)
7.2. North America
7.2.1. North America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.2.2. U.S.
7.2.2.1. U.S. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.2.3. Canada
7.2.3.1. Canada Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.2.4. Mexico
7.2.4.1. Mexico Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3. Europe
7.3.1. Europe Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.2. U.K.
7.3.2.1. U.K. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.3. Germany
7.3.3.1. Germany Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.4. France
7.3.4.1. France Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.5. Italy
7.3.5.1. Italy Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.6. Spain
7.3.6.1. Spain Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.7. Denmark
7.3.7.1. Denmark Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.8. Sweden
7.3.8.1. Sweden Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.3.9. Norway
7.3.9.1. Norway Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4. Asia Pacific
7.4.1. Asia Pacific Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.2. Japan
7.4.2.1. Japan Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.3. China
7.4.3.1. China Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.4. India
7.4.4.1. India Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.5. Australia
7.4.5.1. Australia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.6. South Korea
7.4.6.1. South Korea Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.7. Thailand
7.4.7.1. Thailand Point of Care Infectious Disease Diagnostic Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5. Latin America
7.5.1. Latin America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.2. Brazil
7.5.2.1. Brazil Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.3. Argentina
7.5.3.1. Argentina Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.2. South Africa
7.6.2.1. South Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.4. UAE
7.6.4.1. UAE Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.5. Kuwait
7.6.5.1. Kuwait Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Abbott
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Thermo Fisher Scientific Inc
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. F. Hoffmann-La Roche Ltd
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Siemens Healthineers
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Becton, Dickinson & Company
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Chembio Diagnostics Inc.
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Trinity Biotech
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Cardinal Health
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Quest Diagnostics Incorporated
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Bio-Rad Laboratories Inc.
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
8.4.11. bioMérieux SA
8.4.11.1. Participant’s Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Recent Developments/ Strategic Initiatives
8.4.12. Sight Diagnostics Ltd.
8.4.12.1. Participant’s Overview
8.4.12.2. Financial Performance
8.4.12.3. Product Benchmarking
8.4.12.4. Recent Developments/ Strategic Initiatives
8.4.13. Gene POC
8.4.13.1. Participant’s Overview
8.4.13.2. Financial Performance
8.4.13.3. Product Benchmarking
8.4.13.4. Recent Developments/ Strategic Initiatives
8.4.14. Trivitron Healthcare
8.4.14.1. Participant’s Overview
8.4.14.2. Financial Performance
8.4.14.3. Product Benchmarking
8.4.14.4. Recent Developments/ Strategic Initiatives
8.4.15. OJ-Bio Ltd.
8.4.15.1. Participant’s Overview
8.4.15.2. Financial Performance
8.4.15.3. Product Benchmarking
8.4.15.4. Recent Developments/ Strategic Initiatives
8.4.16. Ortho-Clinical Diagnostics.
8.4.16.1. Participant’s Overview
8.4.16.2. Financial Performance
8.4.16.3. Product Benchmarking
8.4.16.4. Recent Developments/ Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers